Shane Cooke Net Worth

The estimated Net Worth of Shane Cooke is at least $3.23 Million dollars as of 29 June 2024. Mr. Cooke owns over 6,104 units of Alkermes plc stock worth over $2,738,862 and over the last 13 years he sold ALKS stock worth over $149,559. In addition, he makes $341,236 as Director at Alkermes plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cooke ALKS stock SEC Form 4 insiders trading

Shane has made over 65 trades of the Alkermes plc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 6,104 units of ALKS stock worth $162,183 on 29 June 2024.

The largest trade he's ever made was exercising 118,000 units of Alkermes plc stock on 23 January 2015 worth over $1,722,800. On average, Shane trades about 7,652 units every 42 days since 2011. As of 29 June 2024 he still owns at least 103,081 units of Alkermes plc stock.

You can see the complete history of Mr. Cooke stock trades at the bottom of the page.

Shane Cooke biography

Shane M. Cooke is Director of the Company. Mr. Cooke served as our President and as President of Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a member of our Board upon his retirement. In addition, Mr. Cooke has been chairman of the board of directors of APIL since September 2011. Mr. Cooke served as Executive Vice President of Elan Corporation, plc (“Elan”) and Head of Elan Drug Technologies from May 2007 to September 16, 2011 and as the Chief Financial Officer of Elan from July 2001 until May 2011. Mr. Cooke served as a director of Elan from May 2005 to September 16, 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, he held a number of senior finance positions in the banking and aviation industries. He is a chartered accountant. Qualifications and Skills: Mr. Cooke is an Irish citizen, resident in Ireland. His depth of experience in managing Irish corporate entities and his extensive network within the Irish business and finance community, as well as his familiarity with Irish policy and regulation, are highly beneficial to the Company as an Irish-incorporated entity. In addition to Mr. Cooke’s global experience in the pharmaceutical industry, he also has significant experience in business development and transactional activities. Mr. Cooke’s substantial experience as an executive in the biopharmaceutical industry, including serving as a chief financial officer and as a president of publicly-traded companies, brings strategic leadership attributes and expertise in operations, finance, and commercial management to our Board.

What is the salary of Shane Cooke?

As the Director of Alkermes plc, the total compensation of Shane Cooke at Alkermes plc is $341,236. There are 17 executives at Alkermes plc getting paid more, with Richard Pops having the highest compensation of $14,637,100.

How old is Shane Cooke?

Shane Cooke is 57, he's been the Director of Alkermes plc since 2018. There are 14 older and 8 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.

What's Shane Cooke's mailing address?

Shane's mailing address filed with the SEC is CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN, , 4 Ireland.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops und James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.

What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Complete history of Mr. Cooke stock trades at Alkermes plc, Endo International plc und Prothena plc

Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include:

• Richard Pops,
  Chairman of the Board, Chief Executive Officer
• Craig Hopkinson,
  Executive Vice President, Research and Development and Chief Medical Officer
• David Gaffin,
  Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
• James Frates,
  Chief Financial Officer, Senior Vice President
• Michael Landine,
  Senior Vice President - Corporate Development, Chief Risk Officer
• Richard F. Pops,
  Chairman & CEO
• Dr. Craig C. Hopkinson,
  Exec. VP of R&D and Chief Medical Officer
• David Joseph Gaffin,
  Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
• Frank Wilson,
  Independent Director
• Richard Gaynor,
  Independent Director
• Michael J. Landine,
  Sr. VP of Corp. Devel. & Chief Risk Officer
• Paul Mitchell,
  Independent Director
• Robert Breyer,
  Independent Director
• David Anstice,
  Lead Independent Director
• Nancy Snyderman,
  Independent Director
• Wendy Dixon,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Shane Cooke,
  Director
• Iain Brown,
  Senior Vice President - Finance, Chief Accounting Officer
• Peter Norman,
  Sr. VP of Policy & Gov. Relations
• Iain Michael Brown,
  Sr. VP & CFO
• Dr. Floyd E. Bloom M.D.,
  Founder
• Stephen Schiavo,
  Sr. VP of HR
• Eva Stroynowski,
  VP of Product & R&D Communications, Public Affairs
• Sandra Coombs,
  Co-Head of Investor Relations
• Blair C. Jackson,
  Exec. VP & COO
• Dr. Floyd E. Bloom,
  Founder
• Floyd E Bloom,
  Director
• Elliot Ehrich,
  SVP, R&D & CMO, Alkermes, Inc.
• Mark Stejbach,
  Chief Commercial Officer
• James A. Jr. Robinson,
  President & COO,Alkermes, Inc.
• Nancy Lurker,
  Director
• Rebecca Peterson,
  SVP, Corporate Communications
• Geraldine Henwood,
  Director
• Kathryn L Biberstein,
  SVP, GC, Secretary, Alks, Inc.
• Gordon G Pugh,
  SVP, COO & CRO, Alkermes, Inc.
• James L Botkin,
  SVP, Alkermes Gainesville LLC
• Mark B Skaletsky,
  Director
• Corp Plc Elan Science Three...,
  
• Christian Todd Nichols,
  SVP, Chief Commercial Officer
• Brian P Mckeon,
  Director
• David Angelo Jr. Daglio,
  Director
• Blair Curtis Jackson,
  EVP, Chief Operating Officer
• Emily Peterson Alva,
  Director
• Cato T Laurencin,
  Director
• Christopher I Wright,
  Director
• Samuel Joseph Parisi,
  VP, Finance (Interim PAO)